Evidence map›Paper›PMID 10455281›Full record

ArticleBritish journal of pharmacology1999

Protection by imidazol(ine) drugs and agmatine of glutamate-induced neurotoxicity in cultured cerebellar granule cells through blockade of NMDA receptor.

G Olmos, N DeGregorio-Rocasolano, M Paz Regalado, T Gasull, M Assumpció Boronat, R Trullas, A Villarroel, J Lerma, J A García-Sevilla

Open access · greenAbstract readComparative Study
In one paragraph

Article in British journal of pharmacology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 166 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. IGeroScience · 2021
    Article
  6. Article
  7. Imidazoline IPharmacology & therapeutics · 2017
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Effects of opioids, cannabinoids, and vanilloids on body temperature.Frontiers in bioscience (Scholar edition) · 2011
    Review
  17. Article
  18. Article
  19. Agmatine attenuates brain edema through reducing the expression of aquaporin-1 after cerebral ischemia.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2010
    Article
  20. Nitric Oxide Synthase Inhibitors as Antidepressants.Pharmaceuticals (Basel, Switzerland) · 2010
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

G OlmosAssociate Unit of the Institute Cajal/Consejo Superior de Investigaciones Científicas, Department of Biology, University of the Balearic Islands, Palma de Mallorca, Spain.
N DeGregorio-Rocasolano
M Paz Regalado
T Gasull
M Assumpció Boronat
R Trullas
A Villarroel
J Lerma
J A García-Sevilla
Universitat de les Illes Balears · ESConsejo Superior de Investigaciones Científicas · ESInstitut d'Investigacions Biomèdiques de Barcelona · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESInstituto Cajal · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study was designed to assess the potential neuroprotective effect of several imidazol(ine) drugs and agmatine on glutamate-induced necrosis and on apoptosis induced by low extracellular K+ in cultured cerebellar granule cells. Exposure (30 min) of energy deprived cells to L-glutamate (1-100 microM) caused a concentration-dependent neurotoxicity, as determined 24 h later by a decrease in the ability of the cells to metabolize 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) into a reduced formazan product. L-glutamate-induced neurotoxicity (EC50=5 microM) was blocked by the specific NMDA receptor antagonist MK-801 (dizocilpine). Imidazol(ine) drugs and agmatine fully prevented neurotoxicity induced by 20 microM (EC100) L-glutamate with the rank order (EC50 in microM): antazoline (13)>cirazoline (44)>LSL 61122 [2-styryl-2-imidazoline] (54)>LSL 60101 [2-(2-benzofuranyl) imidazole] (75)>idazoxan (90)>LSL 60129 [2-(1,4-benzodioxan-6-yl)-4,5-dihydroimidazole](101)>RX82 1002 (2-methoxy idazoxan) (106)>agmatine (196). No neuroprotective effect of these drugs was observed in a model of apoptotic neuronal cell death (reduction of extracellular K+) which does not involve stimulation of NMDA receptors. Imidazol(ine) drugs and agmatine fully inhibited [3H]-(+)-MK-801 binding to the phencyclidine site of NMDA receptors in rat brain. The profile of drug potency protecting against L-glutamate neurotoxicity correlated well (r=0.90) with the potency of the same compounds competing against [3H]-(+)-MK-801 binding. In HEK-293 cells transfected to express the NR1-1a and NR2C subunits of the NMDA receptor, antazoline and agmatine produced a voltage- and concentration-dependent block of glutamate-induced currents. Analysis of the voltage dependence of the block was consistent with the presence of a binding site for antazoline located within the NMDA channel pore with an IC50 of 10-12 microM at 0 mV. It is concluded that imidazol(ine) drugs and agmatine are neuroprotective against glutamate-induced necrotic neuronal cell death in vitro and that this effect is mediated through NMDA receptor blockade by interacting with a site located within the NMDA channel pore.

Indexed as

AgmatineAnimalsAntazolineBenzofuransCell LineCells, CulturedCerebellumDioxanesDizocilpine MaleateDose-Response Relationship, DrugElectrophysiologyGlutamic AcidHumansIdazoxanImidazolesNeuroprotective Agents2-(1,4-benzodioxan-6-yl)-4,5-dihydroimidazole2-methoxyidazoxan2-styryl-2-imidazolineAgmatineAntazolineBenzofuranscirazolineDioxanesDizocilpine MaleateGlutamic AcidIdazoxanimidazoleImidazolesLSL 60101Neuroprotective AgentsPotassiumReceptors, N-Methyl-D-AspartateStyrenes

Identifiers

PMID10455281
PMCPMC1760666
OpenAlexW1989831685

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.